BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.

Pembrolizumab 200 / Trastuzumab 6 / Cisplatin 80 / Fluorouracil 800, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2+

Protocol-ID: 2102 V1.1 (Mini), PEMB200/TRAS6/CISP80/FU800, AEG/Gastric Ca, C2+


  • Gastric Cancer (HER2+); ICD-10 C16.-, C16.0
  • Esophageal Cancer (Adenocarcinoma Esophagogastric Junction (AEG), HER2+); ICD-10 C15.-


  • Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC). [ASCO Abstracts doi]
The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 20.02.2024